- Home
- ALNY vs TRI Comparison
ALNY vs TRI Comparison
Compare ALNY & TRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALNY | TRI |
|---|---|---|
| Founded | 2002 | 1851 |
| Country | United States | Canada |
| Employees | 115 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.8B | 44.2B |
| IPO Year | 2004 | 2002 |
Fundamental Metrics
Financial Performance| Metric | ALNY | TRI |
|---|---|---|
| Price | $297.61 | $94.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 28 | 12 |
| Target Price | ★ $471.00 | $154.58 |
| AVG Volume (30 Days) | 1.0M | ★ 1.5M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 2.62% |
| EPS Growth | ★ 206.88 | N/A |
| EPS | ★ 2.33 | N/A |
| Revenue | ★ $1,037,418,000.00 | N/A |
| Revenue This Year | $52.67 | $8.90 |
| Revenue Next Year | $31.48 | $7.89 |
| P/E Ratio | $132.48 | ★ $25.72 |
| Revenue Growth | ★ 22.88 | N/A |
| 52 Week Low | $246.00 | $79.71 |
| 52 Week High | $495.55 | $218.40 |
Technical Indicators
Market Signals| Indicator | ALNY | TRI |
|---|---|---|
| Relative Strength Index (RSI) | 39.17 | 54.91 |
| Support Level | N/A | $80.85 |
| Resistance Level | $337.95 | $98.22 |
| Average True Range (ATR) | 12.33 | 3.53 |
| MACD | -1.64 | 0.71 |
| Stochastic Oscillator | 17.28 | 68.27 |
Price Performance
Historical ComparisonAbout ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
About TRI Thomson Reuters Corp
Thomson Reuters is a leading global provider of business information services, delivering trusted data, technology, and expertise to professionals across legal, tax, accounting, risk, compliance, and the news and media sectors. Headquartered in Toronto, Canada, the company combines deep domain knowledge with data and software solutions to help clients make informed decisions, manage complexity, and drive efficiency. Thomson Reuters serves legal and accounting/tax professionals, corporations, and governments worldwide, but around 75% of revenue is generated in the US. The company is known for flagship products such as Westlaw, UltraTax CS, and Reuters News.